SEWOONMEDICAL CO,. LTD.: debt-to-equity, ROE and more
KOSDAQ, Legal name SEWOONMEDICAL CO,. LTD.
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 6.1%
- Equity ratio
- 94.2%
- ROE
- 7.9%
- Op. margin
- 20.0%
- Rev. growth
- 5.8%
- Interest coverage
- n/a
Condition flags
- Operating profit for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
| Fiscal year | Cash dividend per share | Payout ratio |
|---|---|---|
| 2025 | ₩70 | 24.2% |
| 2024 | ₩60 | 20.7% |
| 2023 | ₩70 | 19.6% |
Cash dividends for 3 straight years (only the 3 years OpenDART returns).
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 7.6% | 92.9% | 11.0% | 24.6% | n/a |
| FY2022 consolidated | 6.0% | 94.4% | 8.5% | 20.3% | -3.9% |
| FY2023 consolidated | 6.5% | 93.9% | 11.2% | 24.8% | 13.5% |
| FY2024 consolidated | 5.2% | 95.0% | 8.4% | 18.9% | -11.9% |
| FY2025 consolidated | 6.1% | 94.2% | 7.9% | 20.0% | 5.8% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩62.6B | ₩60.1B | ₩68.2B | ₩60.2B | ₩63.7B |
| Operating profit | ₩15.4B | ₩12.2B | ₩16.9B | ₩11.4B | ₩12.7B |
| Pre-tax income | ₩16.6B | ₩13.6B | ₩19.3B | ₩15.6B | ₩14.9B |
| Net income | ₩12.8B | ₩10.6B | ₩15.5B | ₩12.6B | ₩12.2B |
| Total assets | ₩124.7B | ₩132.5B | ₩146.6B | ₩156.8B | ₩163.9B |
| Total liabilities | ₩8.8B | ₩7.5B | ₩8.9B | ₩7.8B | ₩9.5B |
| Total equity | ₩115.9B | ₩125.0B | ₩137.7B | ₩149.1B | ₩154.4B |
| Paid-in capital | ₩4.4B | ₩4.4B | ₩4.4B | ₩4.4B | ₩4.4B |
| Debt/equity (source value) | 7.6% | 6.0% | 6.5% | 5.2% | 6.1% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 1982-08-06
- Listed
- 08/09/30
- Employees
- 187
- Auditor
- 태성회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1101110324858
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 세운메디칼Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.